Clinical Trial Update: Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial in China is evaluating the efficacy, response, and safety of TareSphere for unresectable hepatocellular carcinoma and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TareSphere

Snippet

Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Conditions: Unresectable Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING